To amend the Patient Protection and Affordable Care Act to address fraudulent enrollments in the Exchanges.

HR7860, the 'Stop ACA Enrollment Fraud Act of 2026,' was introduced in the House on March 9, 2026, and has been referred to the Committees on Energy and Commerce, and Ways and Means. This bill seeks to amend the Patient Protection and Affordable Care Act by establishing a process to identify duplicate Social Security Numbers to prevent erroneous premium tax credit payments and by requiring explicit consent for agent- or broker-assisted enrollments in qualified health plans for plan years beginning on or after January 1, 2027. This bill does not authorize or appropriate specific funding amounts. Its primary mechanism is regulatory, aiming to reduce fraudulent payments of premium tax credits and enhance transparency in agent-assisted enrollments. The financial impact would stem from reduced fraud losses for the government and, indirectly, for health insurers who participate in the ACA exchanges. However, it would also impose new administrative requirements on agents, brokers, and potentially the Exchanges themselves, which could lead to increased operational costs. Structural winners from this legislation, if enacted, would primarily be health insurers operating within the ACA Exchanges, such as UnitedHealth Group ($UNH), Humana Inc. ($HUM), and The Cigna Group ($CI), as they would benefit from a reduction in fraudulent enrollments and associated premium tax credit issues. CVS Health Corporation ($CVS), which has a significant pharmacy benefits management segment and a retail presence, could also see indirect benefits from a more stable and less fraudulent ACA market. Structural losers could include health insurance brokers and agents, who would face increased administrative burdens due to the new consent requirements. The market has shown recent positive trends for these healthcare companies, with UNH up +7.48%, HUM up +10.03%, and CI up +6.82% over the last 7 days, while CVS is up +4.48% in the same period. This suggests a broader positive sentiment in the healthcare sector, independent of this specific bill's early stage. As an early-stage bill, HR7860 has a long legislative path ahead. It must pass through both the House and Senate committees to which it was referred, then receive a vote in both chambers, and finally be signed by the President. The existence of a related bill, HR6515, which also addresses duplicate enrollments, indicates a recognized issue but does not guarantee swift passage for HR7860. The earliest potential impact on market operations would be for plan years beginning on or after January 1, 2027, as specified in the bill text for the consent requirements.